Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

Journal of Diabetes Science and Technology

Volumn 8, Issue 5, 2014, Pages 1011-1017

  Renukuntla, Venkat Sasidhar ^a   Ramchandani, Neesha ^b   Trast, Jeniece ^b   Cantwell, Martin ^c   Heptulla, Rubina A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

artificial pancreas; closed loop; ePID algorithm; exenatide; pramlintide; type 1 diabetes

Indexed keywords

CARBOHYDRATE; EXENDIN 4; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ONDANSETRON; PRAMLINTIDE; AMYLIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ADULT; ALGORITHM; ARTICLE; ARTIFICIAL PANCREAS; ARTIFICIAL PANCREAS CLOSED LOOP SYSTEM; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG MECHANISM; DRUG SAFETY; EXTERNAL PHYSIOLOGICAL INSULIN DELIVERY ALGORITHM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INTERSTITIAL FLUID; MALE; MONOTHERAPY; NAUSEA; POSTPRANDIAL STATE; TREATMENT DURATION; VOMITING; YOUNG ADULT; ADOLESCENT; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; HYPERGLYCEMIA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; ISLET AMYLOID POLYPEPTIDE; MALE; PANCREAS, ARTIFICIAL; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 84929780489     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814542153     Document Type: Article

References (20)

1. Bruttomesso D, Farret A, Costa S, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Technol. 2009;3:1014-1021.
2. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010;4:1374-1381.
3. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368:824-833.
4. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetes Med. 2006;23:1-12.
5. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31:934-939.
6. Wilinska ME, Budiman ES, Taub MB, et al. Overnight closedloop insulin delivery with model predictive control: Assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol. 2009;3:1109-1120.
7. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005;54:1100-1107.
8. Chase HP, Lutz K, Pencek R, Zhang B, Porter L. Pramlintide lowered glucose excursions and was well-Tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr. 2009;155:369-373.
9. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33:1294-1296.
10. Ruiz JL, Sherr JL, Cengiz E, et al. Effect of insulin feedback on closed-loop glucose control: A crossover study. J Diabetes Sci Technol. 2012;6:1123-1130.
11. Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab. 2009;94:1608-1611.
12. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-1143.
13. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes. 2011;60:1599-1607.
14. Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012;35:1994-1999.
15. Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med. 2010;8:542-549.
16. Pencek R, Roddy T, Peters Y, et al. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: A large observational study. Diabetes Obes Metab. 2010;12: 548-551.
17. Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract. 2012;66:1147-1157.
18. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165: 77-84.
19. Kruger AJ, Yang C, Lipson KL, et al. Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity. 2011;44:137-148.
20. Mastrototaro J, Shin J, Marcus A, Sulur G, Investigators SCT. The accuracy and efficacy of real-Time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10:385-390.